These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16137475)

  • 21. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
    Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3.
    MacDonald GA; Bridle KR; Ward PJ; Walker NI; Houglum K; George DK; Smith JL; Powell LW; Crawford DH; Ramm GA
    J Gastroenterol Hepatol; 2001 Jun; 16(6):599-606. PubMed ID: 11422610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase.
    Suzuki A; Okamoto S; Lee S; Saito K; Shiuchi T; Minokoshi Y
    Mol Cell Biol; 2007 Jun; 27(12):4317-27. PubMed ID: 17420279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.
    Svegliati-Baroni G; Candelaresi C; Saccomanno S; Ferretti G; Bachetti T; Marzioni M; De Minicis S; Nobili L; Salzano R; Omenetti A; Pacetti D; Sigmund S; Benedetti A; Casini A
    Am J Pathol; 2006 Sep; 169(3):846-60. PubMed ID: 16936261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatty liver in the intensive care unit.
    Paquot N; Delwaide J
    Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):183-7. PubMed ID: 15716798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of mitochondria in non-alcoholic fatty liver disease.
    Pessayre D
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S20-7. PubMed ID: 17567459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver.
    García-Villafranca J; Guillén A; Castro J
    Biochimie; 2008 Mar; 90(3):460-6. PubMed ID: 17997005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal relationship between diet-induced steatosis and onset of insulin/leptin resistance in male Wistar rats.
    Zhang L; Song H; Ge Y; Ji G; Yao Z
    PLoS One; 2015; 10(2):e0117008. PubMed ID: 25658428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
    An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
    Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation.
    Liu Y; Ma Z; Zhao C; Wang Y; Wu G; Xiao J; McClain CJ; Li X; Feng W
    Toxicol Lett; 2014 Apr; 226(2):117-23. PubMed ID: 24503013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
    Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathogenesis of non-alcoholic fatty liver and potential therapeutic targets].
    Crespo J; Cayón A; Pons-Romero F
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():15-23. PubMed ID: 15195530
    [No Abstract]   [Full Text] [Related]  

  • 40. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.
    Lieber CS
    Alcohol; 2004 Aug; 34(1):9-19. PubMed ID: 15670660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.